A corresponds to the irradiated breast, B corresponds to the boost region, A’ and B’ correspond to the mirror positions in the contra-lateral healthy breast. Figure 5 Increment in skin thickness (%) in the boost (O) and in the irradiated ABT-888 manufacturer breast (□) region (the 34 Gy region) for

the different grades of toxicity. Figure 6 Scatter diagram of the correlation between previous adjuvant chemotherapy and/or concomitant hormonal therapy on skin thickenings. Discussion Several phase III randomized clinical trials [1–3] have evaluated the issue of hypofractionation in early-stage breast cancer showing that hypofractionated adjuvant whole breast radiotherapy after breast-conserving surgery offers equivalent results to those seen with normo-fractionated approach also representing an attractive treatment option because it allows for the shortened course of AR-13324 chemical structure adjuvant RT. However concerns remain about the role of the boost dose in hypofractionated fashion on the overall treatment’s potential GSK2118436 in vivo toxicity to such an extent that the ASTRO task

force, who in 2011 developed an evidence-based guideline to provide direction for whole breast hypofractionation in clinical practice, did not reach unanimous consensus regarding a specific dose-fractionation scheme to use for the boost dose, therefore the ASTRO task force concluded that “on the basis of the published data and the collective expert opinion of the panel, boost doses of 10–16 Gy in 2-Gy fractions or 10 Gy in 2.5-Gy fractions were considered acceptable” [11]. On the other hand in the three randomized trials that contributed to clarify the role of hypofractionation in adjuvant whole breast radiotherapy the boost dose to the tumor bed was not prescribed Atazanavir [1] or was administered (at discretion of physician or according to local indications) in percentage ranging between 42% [2] and 60% [3] always at 2 Gy/fr to a total dose of 10 Gy in five fractions. In addiction the impact of boost dose on late toxicity

was not separately analyzed. In our study 14% of patients developed ≥ G1 late toxicity, this result being in accordance with other published data [12]. Skin fibrosis is a common radiation-induced late effect usually scored by means of eye and palpation-based rating scales that are inevitably affected by examining physician subjective judgment with possible intra ed inter-obsever variability, the same is for cosmetic results or change in breast appearance judged using different, sometimes homemade, scoring systems. In fact the application of different toxicity scoring scales, in conjunction with the possibility of a subjective interpretation of clinical toxicity data, based on visual and tactile examinations, might explain discrepancies in toxicity results between different studies. H. Alexander et al.